 |
|
|
| |
Comparing the incidence and identifying risk factors for nephrolithiasis among patients exposed to atazanavir, other PIs and PI-free regimens
|
| |
| |
Reported by Jules Levin
July 20-25, AIDS 2014 - Melbourne, Australia
Ella Nkhoma, PhD1, Monica Kumar, MD2, Patricia Hines, BA3, Vidya Moorthy, MS4 1Global Pharmacovigilance and Epidemiology (GPVE), Bristol-Myers Squibb (BMS), Wallingford, CT, USA; 2GPVE, BMS, Hopewell, NJ, USA; 3Center for Observational Research and Data Sciences, BMS, Hopewell, NJ, USA; 4Mu Sigma, Northbrook, Illinois, Chicago, USA
|
| |
|
|
|
|
|
